Skip to main content

Table 2 Proportional hazards model for the development of hepatocellular carcinoma

From: Predictive impact of polymorphism of PNPLA3 on HCC development after interferon therapy in Japanese patients with chronic hepatitis C

  Univariate analysis Multivariate analysis
Factors Hazards ratio (range) p Hazards ratio (range) p
Age (years) 1.0 (0.99-1.1) 0.12   
Sex (1: male) 5.6 (1.6-19) 0.0062 5.5 (1.5-21) 0.011
Body mass index 1.2 (1.0-1.3) 0.0086 1.2 (1.0-1.3) 0.029
Liver fibrosis 3.8 (1.9-7.3) <0.0001   
Hepatitis activity 1.1 (0.44-2.6) 0.88   
Liver steatosis (>30%) 2.1 (0.95-4.8) 0.067   
rs 8099917 of IL28B (TT) 0.62 (0.25-1.6) 0.31   
rs 738409 of PNPLA3 (148 M) 0.40 (0.17-0.97) 0.043   
Amino acid 70 of HCV core (glutamine) 3.4 (0.86-14) 0.082   
Alanine aminotransferase (>40 IU/L) 1.2 (0.68-2.2) 0.51   
Platelet count (104/mm3) 0.77 (0.69-0.87) <0.0001 0.76 (0.66-0.88) 0.0002
Alpha fetoprotein (ng/mL) 1.1 (1.0-1.1) 0.0002 1.1 (1.0-1.1) 0.046
HOMA-IR 0.97 (0.79-1.2) 0.76   
Sustained virological response 0.13 (0.03-0.57) 0.0067   
Null or partial virological response 2.4 (1.0-5.9) 0.048   
  1. : 95% confidence interval; PNPLA3, patatin-like phospholipase domain-containing protein 3; HOMA-IR, homeostasis model assessment insulin resistance.